Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
Zhichao Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Aiping Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Liangjun Zhu(Jiangsu Cancer Hospital), Shengbin Shi(Shandong Tumor Hospital), J. Cheng, Jianfeng Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Zuoxing Niu(Shandong Tumor Hospital), Wei Deng(Capital Medical University), Yingying Huang(Nanfang Hospital), Rong Wu(China Medical University), Sheng Li(Jiangsu Cancer Hospital), Wen Zhang(Xidian University), Yan Zhang(Capital Medical University), Yunbo Zhao(University of Science and Technology of China), Feng Xiong(Soochow University), Xiaobing Chen(Zhengzhou University), Chunmei Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunrong Zhu, Yongkun Sun(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 0
Related Papers
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
|Journal of Clinical Oncology|2022|306
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
|Biochemical Pharmacology|2020|160